Volume 2.14 | Apr 15

Prostate Cell News 2.14, April 15, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Probing the Invasiveness of Prostate Cancer Cells in a 3D Microfabricated Landscape
Scientists have constructed a microfabricated chip with a three-dimensional (3D) topology consisting of lowlands and isolated square highlands (Tepuis), which stand hundreds of microns above the lowlands, in order to assess cancer cell metastatic potential as they invade the highlands. [Proc Natl Acad Sci USA]

Closely Monitoring Low-Risk Prostate Cancer, with Biopsy, does not Raise Risk of Death and Discourages Overtreatment
A study of 769 men from across the United States recently diagnosed with low-grade prostate cancer shows that forgoing immediate surgery to remove the tumor or radiation poses no added risk of death. [Press release from Johns Hopkins University School of Medicine discussing online prepublication in the Journal of Clinical Oncology]

Jefferson Doctors Strengthen Case for High-Dose Radiotherapy Technique After Radical Prostatectomy
A widely-available yet expensive radiotherapy technique used to treat prostate cancer patients after surgery has promising benefits—higher dose and less damage to the rectum and bladder—compared to a less precise technique. [Press release from Thomas Jefferson University Kimmel Cancer Center discussing online prepublication in Practical Radiation Oncology]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

A Designed Cell-Permeable Aptamer-Based Corepressor Peptide Is Highly Specific for the Androgen Receptor and Inhibits Prostate Cancer Cell Growth in a Vector-Free Mode
Using a yeast peptide aptamer two-hybrid screen with the full-length human androgen receptor (AR), researchers identified a short amino acid-stretch that binds specifically to the human AR in yeast and in mammalian cells and not to the closely related progesterone or glucocorticoid receptors. [Endocrinology]

Insulin-Like Growth Factor-Binding Protein-2 Promotes Prostate Cancer Cell Growth Via Insulin-Like Growth Factor-Dependent or -Independent Mechanisms and Reduces the Efficacy of Docetaxel
The aim of this study is to investigate the effects of insulin-like growth factor-binding protein-2 on prostate cancer cell proliferation and its effects on the response to docetaxel. [Br J Cancer]

Bone Marrow-Derived Macrophages Are Associated with Androgen Modulated Prostate Regeneration
The observation that bone marrow-derived macrophages are recruited into the prostate where they associate with prostate regeneration suggests that bone marrow-derived macrophages are involved in prostate regeneration. [Prostate]

Chemotherapy Sensitivity Recovery of Prostate Cancer Cells by Functional Inhibition and Knock Down of Multidrug Resistance Proteins
Using primary cell cultures from prostate cancer patients, researchers evaluated the effect of function and expression inhibition of p-glycoprotein, MRP1, and LRP, on cell survival after chemotherapy exposure. [Prostate]

Combined Treatment Targeting HIF-1α and Stat3 Is a Potent Strategy for Prostate Cancer Therapy
To develop a potent strategy to increase therapeutic efficacy and reduce drug resistance in prostate cancer therapy, investigators combined two anti-cancer agents: T40214 (a p-Stat3 inhibitor) and JG244 (a hypoxia-inducible factor-1α (HIF-1α) inhibitor) together to treat nude mice bearing human prostate tumor (DU145) and immunocompetent mice (C57BL/6) bearing murine prostate tumor (TRAMP-C2). [Prostate]


Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
The purpose of this study is to assess the outcomes of men with prostate cancer enrolled in active surveillance. [J Clin Oncol]

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients with Castration-Resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of docetaxel plus high-dose calcitriol (DN-101) to docetaxel plus prednisone in an open-label Phase III trial. [J Clin Oncol]

Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
The purpose of this study is to evaluate the tolerability of escalating doses of stereotactic body radiation therapy in the treatment of localized prostate cancer. [J Clin Oncol]

Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting
The objective of this study is to compare the diagnostic accuracy of PSA isoform p2PSA and its derivatives in determining the presence of prostate cancer at initial biopsy with the accuracy of other predictors in patients with total PSA 2.0-10 ng/ml. [Eur Urol]

The Sensitivity of [11C]Choline PET/CT to Localize Prostate Cancer Depends on the Tumor Configuration
The purpose of this study is to evaluate the dependency of the sensitivity of [11C]choline-PET/CT for detecting and localizing primary prostate cancer on tumor configuration in the histologic specimen. [Clin Cancer Res]

Decision Tree-Based Modeling of Androgen Pathway Genes and Prostate Cancer Risk
The objective of this analysis is to evaluate interactions for prostate cancer risk using classification and regression trees and to evaluate whether these interactive effects add information about risk prediction beyond that of “traditional” risk factors. [Cancer Epidemiol Biomarkers Prev]

Potential for Dose Escalation in the Postprostatectomy Setting with Intensity-Modulated Radiation Therapy: A Dosimetric Study Using EORTC Consensus Guidelines for Target Volume Contours
This study is designed to compare intensity-modulated radiation therapy versus 3-dimensional conformal radiation therapy planning. [Pract Radiat Oncol]
First Patients to Receive New Cancer Drug
The Institute of Cancer Research is pleased to announce that an experimental drug it helped discover has started Phase I safety testing in patients with a range of cancer types. [The Institute of Cancer Research]

Multi-Center Trial Examines New Diagnostic, Screening Tools for Prostate Cancer
Backed with a $3.1 million grant from the National Institutes for Health, physicians at Beth Israel Deaconess Medical Center have embarked on a multi-pronged study to examine whether new urine-based tests that detect genetic abnormalities present in prostate cancer will help doctors more accurately diagnose and screen for prostate cancer. [Beth Israel Deaconess Medical Center Press Release]

IsoRay Inc. Receives $500,000 in Additional Financing
IsoRay Inc. has received an additional $500,000 in institutional financing. Together with the financing closed in November 2010 and the Company’s improved operations, it continues to add to its cash reserves as it aggressively pursues further development of programs expanding the use of its ground-breaking Cesium-131 brachytherapy seeds (internal radiation therapy). [IsoRay, Inc. Press Release]

Theragenics Signs North American Distribution Agreement with Oncura, a Unit of GE Healthcare
Theragenics Corporation announced it has signed an agreement to be a non-exclusive North American distributor with Oncura, Inc. for its brachytherapy-related products, including the implantable, iodine-125 based OncoSeed™, the most globally-available of its kind. [Theragenics Corporation Press Release]

iCAD Granted U.S. Patent on MRI Image Analysis Solutions
iCAD, Inc. announces that the United States Patent and Trademark Office recently granted the company Patent Number 7,903,853. [iCAD, Inc. Press Release]
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW American Association for Cancer Research: Metabolism and Cancer
October 16-19, 2011
Baltimore, United States

NEW 10th Annual American Association for Cancer Research Conference on Frontiers in Cancer Prevention Research
October 22-25, 2011
Boston, United States

Visit our events page to see a complete list of events in the prostate cell community.
Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Fellow (University of Houston – Center for Nuclear Receptors and Cell Signaling)

Postdoctoral Fellow (New Jersey Medical School)

Assistant/Associate Research Scientist (New York University)

Postdoctoral Research Associate (Meharry Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us